BHCM
VOR icon

Brevan Howard Capital Management’s Vor Biopharma VOR Stock Holding History

Brevan Howard Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,217
Closed -$753K – 2621
2026
Q1 		$753K Buy
+42,217
New +$595K 0.01% 1065

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Brevan Howard Capital Management's VOR Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 42,217 shares — an estimated $753K sold.

Brevan Howard Capital Management first reported a position in VOR in Q1 2026 and held it in 1 quarter. The position peaked at $753K in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 42,217 Vor Biopharma shares in Q2 2026, an estimated $753K.
  • Brevan Howard Capital Management first reported a position in Vor Biopharma in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Vor Biopharma position peaked at $753K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.